ERGOT DERIVATIVES AND NNRTIS - DELAVIRDINE OR EFAVIRENZ
Delavirdine and efavirenz are predicted to inhibit the metabolism of ergot derivatives, which may result in the development of ergotism.
The manufacturers generally contraindicate potent CYP3A4 inhibitors which would include delavirdine and efavirenz.
The manufacturers generally contraindicate potent CYP3A4 inhibitors which would include delavirdine and efavirenz.